Gulbenkian Institute for Molecular Medicine

What Gulbenkian Institute for Molecular Medicine does

The Gulbenkian Institute for Molecular Medicine (GIMM) is a Portuguese private research foundation headquartered at the Hospital de Santa Maria campus in Lisbon, formed in 2023 through the merger of Instituto de Medicina Molecular João Lobo Antunes (iMM, founded 2002) and Instituto Gulbenkian de Ciência (IGC, founded 1961). The institute operates as a single multidisciplinary biomedical research organization spanning roughly 785 researchers across 34 laboratories and 9 specialized scientific and clinical platforms (Rodent, Aquatic, Bioimaging, Flow Cytometry, Histopathology, Electron Microscopy, Genomics, Proteomics, and Metabolomics), with a research portfolio covering cancer, infectious disease, neurosciences, immunity and inflammation, aging, and rare/pediatric diseases. Co-location adjacent to the Faculty of Medicine of the University of Lisbon and the largest university hospital in Portugal (CHULN / Hospital de Santa Maria) enables direct clinical-translational integration, anchored by the GIMM CARE Center of Excellence and its next-generation biobank (which holds samples from over 2,800 brain tumor patients, among other cohorts).

GIMM's core products are research infrastructure and translational programs rather than commercial goods: the 9 fee-for-service scientific platforms, the Open Lab initiative for industry- and competitively-funded external projects, the GIMM CARE clinical research and biobank operation (partnered with Vall d'Hebron Institut de Recerca), the annual GIMM Festival public science event (inaugurated 2025), the Beyond GIMM AI-powered public engagement platform (built on Anthropic's Claude), and education programs spanning PhD, postdoctoral, MSc, and internship tracks. As a non-profit foundation, GIMM does not sell commercial products; its revenue model is a mix of competitive institutional grants (European Union Teaming for Excellence and Horizon Europe, Portuguese FCT, PRR, Portugal 2030, Lisboa 2030, COMPETE 2030), philanthropic funding from Fundação Calouste Gulbenkian and "la Caixa" Foundation, individual and corporate donations, fee-for-service platform access, and cause-marketing corporate partnerships. Three spin-offs, 23+ active research awards among principal investigators, and a recent formal Portuguese government recognition (Joint Order No. 11691/2024) of the foundation's scientific nature underscore its positioning as Portugal's only private foundation dedicated exclusively to biomedical research.

Name

Gulbenkian Institute for Molecular Medicine

Legal name

Fundação GIMM – Gulbenkian Institute for Molecular Medicine

Website

https://gimm.pt

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Gulbenkian Institute for Molecular Medicine (GIMM) is a Portuguese private research foundation formed in 2023 through the merger of iMM and IGC, conducting multidisciplinary biomedical research across 34 laboratories and 9 scientific platforms, serving academic researchers, clinicians, industry partners, and patients primarily in Portugal.

Ownership category

akta.pro rank

Product category

Biomedical Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI)

akta.pro secondary industries

Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Biomedical research
• Molecular medicine
• Clinical research
• Translational research
• Scientific platforms

Headquarters

HQ city

Lisbon

HQ country

Portugal

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Donations and Charitable Contributions: Individual and corporate donations supporting specific research areas (aging, cancer, cardiovascular diseases, inflammation, pediatric/rare diseases) and general research at GIMM. One-time and recurring donation options available.
2. Government and Institutional Funding: Funding from Portuguese government entities (FCT, PRR, Portugal 2030, Lisboa 2030), European Union programs (Horizon Europe, Teaming for Excellence), and institutional funders including Gulbenkian Foundation, "la Caixa" Foundation, and others
3. Research Services: Fee-for-service research platform access and services including metabolomics, proteomics, genomics, and other scientific platform services for external researchers
4. GIMM CARE Clinical Research: Clinical research support services and collaborative research projects with industry partners, healthcare providers, and international research institutions

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Core offering

Gulbenkian Institute for Molecular Medicine (GIMM) is a Portuguese private research foundation that conducts multidisciplinary biomedical research spanning fundamental discoveries to clinical and translational applications. It operates 34 research laboratories and nine scientific and clinical platforms (Rodent, Aquatic, Bioimaging, Flow Cytometry, Histopathology, Electron Microscopy, Genomics, Proteomics, and Metabolomics) and delivers clinical research support through its GIMM CARE branch.

Product overview

GIMM (Gulbenkian Institute for Molecular Medicine) is a Portuguese private research foundation established in 2023 through the merger of Instituto de Medicina Molecular João Lobo Antunes (iMM) and Instituto Gulbenkian de Ciência (IGC). The organization operates as a unified platform with multiple interconnected products and services: the core research institute conducting fundamental and translational biomedical research through 34 laboratories; GIMM CARE as its clinical research arm with a dedicated biobank and clinical research support facility; nine Scientific and Clinical Platforms (Rodent, Aquatic, Bioimaging, Flow Cytometry, Histopathology, Electron Microscopy, Genomics, Proteomics, Metabolomics) providing shared infrastructure services; an Open Lab initiative for collaborative external projects; the annual GIMM Festival science outreach program; the Beyond GIMM AI-powered interactive data visualization tool; and Podcast Curiosamente for public science communication. Together these products span the full research continuum from basic discovery through clinical application to public engagement.

Differentiator

Problem solved

Functional benefit

Brands

• GIMM CARE: A branch of GIMM dedicated to the application of scientific knowledge to improve healthcare and quality of life. It aims to revolutionize clinical and translational research by creating a pioneering Center of Excellence in Portugal.

Products and services

• GIMM Gulbenkian Institute for Molecular Medicine Portuguese private research foundation pioneering groundbreaking research from fundamental discoveries to innovative healthcare solutions, established in 2023 through the merger of iMM and IGC.
• GIMM CARE Clinical and translational research branch of GIMM dedicated to improving healthcare and quality of life through a pioneering Center of Excellence in human-centered clinical research.
• Scientific and Clinical Platforms

Quantifiable outcome

• iMM had 485 researchers of 25 nationalities in 30 groups; IGC had 300 researchers of 45 nationalities in 27 groups
• +3 more outcomes

Named customers3 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Partnerships

18 partnerships are on record, tiered minor, significant, core and historical.

• SIC NoticiasminorGTM or Marketing Partner · 1 January 2026Media partner for GIMM Festival 2026
• ExpressominorGTM or Marketing Partner · 1 January 2026Media partner for GIMM Festival 2026
• JCDecaux PortugalminorGTM or Marketing Partner · 1 January 2026Media partner for GIMM Festival 2026
• Ciência VivasignificantGTM or Marketing Partner · 1 January 2026Event partner for GIMM Festival 2026, bringing science education activities to the festival including interactive games and experiences related to microbiology
• Pavilhão do ConhecimentosignificantGTM or Marketing Partner · 1 January 2026Event partner for GIMM Festival 2026, co-located at Parque das Nações area near Pavilhão de Portugal
• Oceanário de LisboasignificantGTM or Marketing Partner · 1 January 2026Event partner for GIMM Festival 2025 with activities on aging and longevity of marine species, including immersive virtual reality experiences in aquarium setting
• Câmara Municipal de LisboasignificantGTM or Marketing Partner · 1 January 2026City of Lisbon is an event partner for GIMM Festival 2026, with Mayor Carlos Moedas participating in opening session
• Sociedade Portuguesa de MicrobiologiaminorGTM or Marketing Partner · 1 January 2026Event partner for GIMM Festival 2026
• Digibéria/DELLminorGTM or Marketing Partner · 1 January 2026Sponsor providing coffee break during GIMM Festival 2026 scientific sessions
• ULisboa (Universidade de Lisboa)coreStrategic or Co-development Partner · 1 January 2026Host university for GIMM, with Faculty of Medicine of Lisbon providing clinical research partnership and co-location at Hospital Santa Maria campus
• ULS Santa MariacoreStrategic or Co-development Partner · 1 January 2026Centro Hospitalar Universitário Lisboa Norte (Hospital Santa Maria) providing clinical partnership and co-location with GIMM Lisbon site
• Penha Longa ResortminorGTM or Marketing Partner · 1 January 2025Charity golf tournament and dinner partner hosting second annual fundraising event. Over 75 players participated in golf tournament and ~120 guests attended charity dinner. Raised €27,000 for breast cancer research. Chef Sergi Arola curated gastronomic experience for dinner.
• National Ballet CompanyminorGTM or Marketing Partner · 1 January 2025Solidarity partnership for Forsythe/McNicol/Balanchine General Rehearsal event at Teatro Camões. Event supported GIMM research with 286 participants. Showcased connection between science and art through public cultural engagement.
• CA Vida (Crédito Agrícola Insurance)significantGTM or Marketing Partner · 1 January 2024Corporate partnership supporting breast cancer research by funding Dr. Ana Magalhães in the Advanced Breast Cancer Translational Laboratory. Includes employee engagement activities such as blood donation drives (86 employees participated, generating 344 plasma, 344 serum, and 86 DNA samples). Partnership duration of one year with planned joint activities.
• Everything is NewsignificantGTM or Marketing Partner · 1 January 2024NOS Alive music festival organizer partnership for annual science engagement at festival. Partnership has supported 24 young researchers through NOS Alive scholarships, funding 12-month integration in GIMM laboratories.
• Associação LaçohistoricalStrategic or Co-development Partner · 1 January 2024Breast cancer advocacy organization (founded 2001) that transitioned its mission to iMM (now GIMM) after realizing need for deeper understanding of cancer biology. Founded Bolsa Laço as breast cancer science incubator before closing association and transferring mission to GIMM.
• Vall d'Hebron Institut de Recerca (VHIR)coreStrategic or Co-development Partner · 1 January 2023International partnership with VHIR in Barcelona, Spain for joint establishment of GIMM CARE as a pioneering Center of Excellence in human-centered clinical and translational research in Portugal. VHIR promotes biomedical research, innovation, and teaching at Vall d'Hebron University Hospital and has worked since 1994 to identify and implement solutions to health problems with national and international leadership in clinical and translational biomedical research.
• FITNESS cerealsminorGTM or Marketing Partner · 1 January 2013Annual October breast cancer awareness campaign (Pink Month) supporting GIMM CARE breast cancer research. Previously supported Laço Association (2013-2023) and iMM-Laço Hub before transitioning to GIMM Foundation. Campaign includes consumer awareness about early breast cancer diagnosis.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Institut Pasteur: A globally recognized private biomedical research foundation with a broad infectious disease and fundamental research portfolio. Comparable in foundation structure, multidisciplinary scope, and integration of research with public health translation, though substantially larger and more globally distributed than GIMM.
• Max Planck Institutes (Life Science cluster): Germany's Max Planck Society operates multiple life science institutes with foundation-style governance, fundamental research focus, and shared technology platforms. Comparable in non-university research institute model and platform-sharing infrastructure, though distributed across many sites.
• Wellcome Sanger Institute: UK-based genomic and biomedical research institute with deep platform infrastructure and a translational mission supported by Wellcome Trust funding. Comparable in foundation-backed governance, genomics platform emphasis, and large-scale collaborative science model.
• Karolinska Institutet: Sweden's premier medical university, combining fundamental biomedical research with clinical integration at Karolinska University Hospital. Comparable in medical school adjacency, hospital co-location, and translational research mission, but at substantially larger scale.
• Francis Crick Institute: London-based biomedical discovery institute operating as a charity with ~1,500 scientists and extensive shared technology platforms. Comparable in foundation governance, platform-centric operating model, and translational ambition, with a larger scale and longer operating history than GIMM.

Direct peers

• Vall d'Hebron Institut de Recerca (VHIR): VHIR is GIMM CARE's explicit strategic partner — a Barcelona-based biomedical research institute co-located with a major university hospital (Vall d'Hebron). It offers the closest direct comparison in scope (translational and clinical research, platform services, hospital integration) and serves as the model for GIMM's clinical research build-out.
• Champalimaud Foundation: Lisbon-based private biomedical research foundation operating the Champalimaud Centre for the Unknown with a translational and clinical research mission. The closest Portuguese peer to GIMM in foundation structure, translational orientation, and Lisbon-based medical research activity.
• Centre for Genomic Regulation (CRG): Barcelona-based biomedical research institute focused on genomics, proteomics, and computational biology with shared core facilities. Comparable in Iberian positioning, advanced research platforms, and translational orientation; serves a similar role in the Southern European biomedical ecosystem.
• Berlin Institute of Health (BIH): German translational research institute jointly hosted by Charité university hospital, focused on turning fundamental research into clinical applications. Comparable in hospital-integrated translational research model, shared platform structure, and foundation-style governance.

Regional players

• Instituto de Tecnologia Química e Biológica António Xavier (ITQB NOVA): Portuguese R&D institute within the Universidade Nova de Lisboa, focused on biological and chemical sciences. Comparable as a Portuguese research institute with shared platforms and graduate training, though it competes with GIMM for national funding and talent in the same country.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/GIMM_Institute
• Facebookfacebook.com/gimm.institute
• LinkedInlinkedin.com/company/gulbenkianinstituteformolecularmedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Gulbenkian Institute for Molecular Medicine